Skip to main content

Table 5 Common symptoms reported within 6 months before enrollment (≥15% of adult patients in either cohort)

From: The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics

Parameter, n (%) rhPTH(1-84)
(n=60)
Conventional therapy
(n=571)
Analysis populationa
(N=631)
Fatigue 31 (51.7) 229 (40.1) 260 (41.2)
Paresthesia 31 (51.7) 169 (29.6) 200 (31.7)
Muscle twitching 29 (48.3) 125 (21.9) 154 (24.4)
Muscle cramping 25 (41.7) 193 (33.8) 218 (34.5)
Headache 20 (33.3) 105 (18.4) 125 (19.8)
Muscle pain 17 (28.3) 112 (19.6) 129 (20.4)
Brain fog 17 (28.3) 95 (16.6) 112 (17.7)
Muscle weakness 17 (28.3) 88 (15.4) 105 (16.6)
Tetany 17 (28.3) 71 (12.4) 88 (13.9)
Joint pain 16 (26.7) 138 (24.2) 154 (24.4)
Anxiety 16 (26.7) 118 (20.7) 134 (21.2)
Weakness in extremities 12 (20.0) 83 (14.5) 95 (15.1)
Pain in extremities 11 (18.3) 83 (14.5) 94 (14.9)
Bone pain 11 (18.3) 76 (13.3) 87 (13.8)
Constipation 11 (18.3) 72 (12.6) 83 (13.2)
Nausea 11 (18.3) 52 (9.1) 63 (10.0)
Back pain 9 (15.0) 106 (18.6) 115 (18.2)
  1. rhPTH(1-84) recombinant human parathyroid hormone (1-84)
  2. aThe assessment at enrollment (visit 1) was defined as baseline; pediatric patients (n=27), those who received rhPTH(1-34) (n=14), and those who initiated rhPTH(1-84) before enrollment (n=65) were excluded from the analysis